Wegovy has 4 Indian generic equivalents now. They're not the same. Here's the teardown.

You priced Wegovy. $1,349-1,800/month, list. Your insurance said no.

You found the NovoCare Direct option ($349-499/mo self-pay). Still steep.

You went one click further and found Reddit talking about generic semaglutide pens via personal-import for $95-370/mo depending on brand and dose. Not one brand. Four.

So which one.

Wegovy is Novo Nordisk's brand of semaglutide injection. The patent on the molecule expired in India in March 2026 (per CDSCO public approval listings), and within months four global pharma giants had launched their own generic semaglutide pens. Same peptide. Different pens, different ladders, different price.

Here's what's actually different between them — because it isn't the molecule.

The four contenders

All four are semaglutide. Same peptide as Wegovy. Same peptide as Ozempic. The only difference between Wegovy and Ozempic is the brand name and the FDA indication on the label — Novo Nordisk literally markets the same molecule twice for different doctors. Indian generics are the third clone.

You're not choosing a different drug. You're choosing a different pen, made by a different factory, priced differently, with a different commitment to carrying the full titration ladder.

TL;DR if you don't want the deep dive: start titration on Noveltreat (Sun Pharma) for weeks 1-12, then switch to Semasize Plus (Alkem) at week 13+ for maintenance. Noveltreat is the only brand that carries the 0.25mg starter and the 0.5mg early-titration pen. Semasize Plus is a 4-week multi-dose pen at $135/month at 2.4mg maintenance — vs. $370/month for Noveltreat at the same dose. So the optimal split is: full ladder for titration, cheaper pen format once stable. Reasoning below if you want to optimize differently.

What "same peptide" actually means

Semaglutide is a 31-amino-acid GLP-1 receptor agonist. The molecule is identical regardless of who synthesizes it — the same way generic atorvastatin is identical to Lipitor.

The Indian regulatory pathway (CDSCO / DCGI) requires bioequivalence demonstration before approval. The pens themselves go through device validation. None of this is the wild west.

Sun Pharma, Dr. Reddy's, and Alkem are not corner-shop operations. They're the largest, second-largest, and fifth-largest Indian pharmaceutical companies by revenue, with USFDA-inspected manufacturing facilities, ANDA filings in the US market, and decades of generic supply to North America and Europe under the standard Hatch-Waxman generic regime.

When you pick up an Indian generic semaglutide pen, you're holding a peptide that came off a fill line that, last month, may have been filling a US-bound generic for a US pharmacy chain. The pen itself is what differs.

Brand 1: Noveltreat (Sun Pharma) — the full ladder

Sun Pharma is India's largest pharmaceutical company by revenue (₹20,812 crore FY24, roughly $2.5B), built on a 30-year acquisition spree that included Ranbaxy in 2014. Their US ANDA filings are the highest of any Indian manufacturer.

Noveltreat carries the full Wegovy titration ladder — 0.25, 0.5, 1.0, 1.7, and 2.4 mg pens. This matters more than it sounds.

Wegovy's titration schedule is escalating: weeks 1-4 at 0.25mg, weeks 5-8 at 0.5mg, weeks 9-12 at 1.0mg, weeks 13-16 at 1.7mg, week 17+ at 2.4mg maintenance. Skipping doses is what causes the GI side effects everyone talks about. Going straight to 1.0mg from zero is how you end up vomiting for a week.

A generic that only carries 0.5mg and 1.0mg forces you to either start at the wrong dose or piece together your titration from two different brands week by week. Noveltreat doesn't make you do that. Same dose strengths, same color-coded pens, same titration logic Novo Nordisk built into Wegovy.

Per-pen cost ranges from $127 (0.25mg starter, 2-week pen) to $185 (2.4mg maintenance, 2-week pen). Sun Pharma ships single-strength 2-week pens, so monthly cost at 2.4mg/wk maintenance is roughly $370/month. That's about 20-27% of Wegovy's $1,349-1,800/month list price. (For lower per-month maintenance cost, Alkem's Semasize Plus at $135/month is the cheaper option — see below.)

Brand 2: Semasize / Semasize Plus (Alkem) — split-brand titration

Alkem is a top-five Indian pharma (₹9,055 crore FY24), strongest in oncology and biosimilars — meaning they have the cold-chain manufacturing infrastructure that pen-format injectables actually require. They run USFDA-approved facilities in India.

Alkem's catalog choice is unusual: they split the titration into two brand identities. Semasize carries the mid-ladder dose (1.0 mg). Semasize Plus carries the maintenance doses (1.7, 2.4 mg). Same molecule, same factory, two boxes.

The split is largely commercial — Alkem markets Semasize Plus as the "maintenance" brand to physicians who've titrated patients up successfully and want a cleaner pharmacy line for chronic refills. From a medical standpoint there's nothing different in the pens.

What you actually get: maintenance coverage at much lower monthly cost than Noveltreat — because the pen format is different. Semasize Plus is a 4-week multi-dose pen ($120 at 1.7mg/wk, $135 at 2.4mg/wk = $120-135/month). Noveltreat 2.4mg is a 2-week single-strength pen at $185, so monthly is $370. Same molecule, same indication, 64% cheaper per month at maintenance, simply because Alkem chose a 4-week pen format and Sun Pharma chose 2-week.

The catch: Semasize / Semasize Plus doesn't carry the 0.25mg starter or 0.5mg early-titration pen. If you're starting fresh, you'll need a different brand for weeks 1-8 of the ladder, then you can move to Semasize 1.0mg in week 9 and Semasize Plus from week 13 onward. Mid-ladder brand switching is harmless from a molecule standpoint (it's all semaglutide), but it's an operational step people don't expect.

Brand 3: Sematrinity (Sun Pharma) — partial ladder

This one is interesting because it's also Sun Pharma — the same company as Noveltreat — but a separate brand identity covering only the 0.5 and 1.0 mg pens.

No 0.25mg starter. No 1.7 / 2.4 mg maintenance. Just the middle of the titration.

Why does this exist? Best guess from the Indian pharma listings: Sun Pharma operates Sematrinity as a domestic-market-positioned brand for the type-2 diabetes Ozempic-equivalent indication, where 0.5-1.0mg covers most prescribing. Noveltreat is the obesity-positioned brand carrying the full Wegovy ladder. Same factory, same molecule, different commercial framing.

For a personal-import buyer this means: if you're a type-2 diabetic stabilized at 1.0mg/week (a common diabetes dose, vs. the 2.4mg/week obesity maintenance), Sematrinity at $142 is a few dollars cheaper than the equivalent Noveltreat 1.0mg pen at $146. If you need 2.4mg, Sematrinity doesn't carry it, period.

Brand 4: Obeda (Dr. Reddy's) — early-to-mid titration, with a packaging twist

Dr. Reddy's is the second-largest Indian generic pharma, ~₹16,963 crore FY24, particularly strong in biosimilars and complex generics. Top-3 Indian pharma globally.

Obeda's pens carry 2.0 and 4.0 mg of total semaglutide content per pen — and this is where it gets unintuitive. Obeda is a 4-weekly-dose multi-dose pen: the 2 mg pen delivers 0.5 mg per week for four weeks (a one-month supply at the week 5-8 dose); the 4 mg pen delivers 1.0 mg per week for four weeks (a one-month supply at the week 9-12 dose).

In titration terms, that means Obeda covers early-to-mid ladder — roughly week 5 through week 12 of the standard Wegovy schedule. It does NOT carry the maintenance doses (1.7 or 2.4 mg/week). And it doesn't carry the 0.25 mg/week starter strength either.

It's a useful brand for someone in month two through three of titration. The one-pen-per-month cadence ($95 for 4 weeks at 0.5mg/wk, $115 for 4 weeks at 1.0mg/wk) is genuinely cheaper than the equivalent month sourced from Noveltreat (where you'd buy 2× $131 = $262 at 0.5mg/wk, or 2× $146 = $292 at 1.0mg/wk). Per-week of dosing, Obeda is the cheapest option in the ladder by roughly 60%.

What it isn't: a standalone solution. You'll need a Noveltreat 0.25mg pen for week 1-4 (no other brand in our catalog carries the starter dose), and you'll need a Semasize Plus or Noveltreat 1.7/2.4mg pen for week 13 onward. Obeda is a slot-filler, not a full ladder.

Dr. Reddy's manufacturing reputation is genuinely strong — the same company that ships ANDAs to US pharmacy chains daily. The total-content pen format (vs. the one-strength-per-pen format that Sun Pharma and Alkem ship) is also a different physical device, which is worth knowing if you have a strong preference for one click-dial style.

The metaphor: same engine, four different cars

If you've ever bought a car, you know that the same engine block ships in three different vehicles at three different price points with three different trim levels. Sometimes the same engine ships in a Porsche and a VW, depending on how the manufacturer wants to position it.

Semaglutide is the engine. The manufacturer assembles it into a pen. The pen is the trim level. Sun Pharma ships two trim levels (Noveltreat full ladder, Sematrinity partial). Alkem ships a split brand (Semasize / Semasize Plus). Dr. Reddy's ships an early-to-mid titration configuration (Obeda) using a different pen format — multi-dose 4-week pens instead of single-strength weekly pens.

Wegovy is the same engine in a Porsche-priced trim. NovoCare Direct is the same engine in a Porsche-discount trim. The Indian generics are the same engine in a Honda Civic.

The Civic gets you to work. The work being done is the peptide doing the work, not the badge.

Cost-of-treatment by tier — monthly and 5-year (at 2.4 mg/week maintenance)

The spread between brand and generic is enormous — at the 2.4mg/week maintenance dose, Semasize Plus is 10-13x cheaper than brand Wegovy and 2.7x cheaper than the most expensive Indian generic option (Noveltreat 2.4mg, where Sun Pharma's pen format is single-strength 2-week pens so you buy two per month at $185 each).

On a five-year horizon, the difference between brand Wegovy and Semasize Plus is roughly $73,000 to $100,000. That gap is the actual reason this article exists.

The interesting cost moves aren't between Indian generics. They're between any Indian generic and the rest of the column.

Counter-narrative: "telehealth is the cheap option"

The standard advice for someone priced out of Wegovy retail is to go to Hims, Eden, Ro Body, or a TRT clinic that's added a GLP-1 module. The marketing makes it sound like a cost-conscious choice.

It isn't, particularly.

Hims's Wegovy Pen at $199/mo is genuinely cheap relative to retail brand — but that's a volume-contract play with Novo Nordisk specifically because Wegovy demand collapsed once the shortage closed and compounded supply dried up. Hims is now competing on Novo's actual product. Eden, Ro Body, and TRT clinics are routing compounded semaglutide at $200-400/mo, which puts them in the same per-month bracket as Indian generic — but with the regulatory uncertainty that compounded semaglutide now sits inside post-shortage (the 503A grace period closed April 22, 2025).

If your reason for not going to a personal-import lane is "I want a US-credentialed prescriber writing me a script," telehealth is the right answer and the price premium is the price of that legal/operational layer. If your reason is cost, telehealth and Indian generic are roughly comparable, with Indian generic cheaper by a margin that grows the longer you stay on the drug.

The decision framework

Pick Noveltreat (Sun Pharma) if:

• You're starting fresh and want the full Wegovy titration ladder in one brand
• You value the largest Indian pharma's manufacturing reputation
• You'd rather pay the per-pen premium ($146 vs Semasize's $100 at 1.0mg, $173 vs Semasize Plus's $120 at 1.7mg) for the convenience of one brand across all five doses

Pick Semasize Plus (Alkem) if:

• You're already past week 12 and want the cheapest 1.7 or 2.4mg maintenance pen ($120 / $135)
• Alkem's biosimilar / cold-chain manufacturing pedigree is reassuring to you
• You're fine sourcing the 0.25mg starter and 0.5mg pens from Noveltreat for the early weeks (Semasize starts at 1.0mg)

Pick Sematrinity (Sun Pharma partial) if and only if:

• You're a type-2 diabetic prescribed at 0.5 or 1.0 mg/week as your stable dose, AND
• You will never need to escalate above 1.0 mg/week, AND
• You want Sun Pharma manufacturing at $4-8/pen below Noveltreat for the same weekly dose ($123 vs $131 at 0.5mg, $142 vs $146 at 1.0mg)

If you might escalate later, skip Sematrinity — switching brands is harmless but switching is itself friction.

Pick Obeda (Dr. Reddy's) if you're at 0.5 mg/week or 1.0 mg/week (i.e. early-to-mid ladder, week 5-12 of the standard schedule), and:

• You like the multi-dose pen format (one Obeda pen = 4 weekly doses; Noveltreat ships single-strength 2-week pens, so you'd buy two per month)
• Per-month cost matters: Obeda's $95 (4 weeks at 0.5mg/wk) vs. Noveltreat's $262 (2× $131 pens for the same 4 weeks at 0.5mg/wk) — that's a $167/month gap at the early titration dose
• You're okay knowing Obeda doesn't carry maintenance doses, so if you escalate past week 12, you're switching brands

For most people landing here for the first time — start with Noveltreat for weeks 1-12 (it has the only 0.25mg starter pen and the only 0.5mg pen in our catalog), then switch to Semasize Plus at week 13+ for maintenance. The switch is harmless (same peptide, same regulatory pathway) and the per-month savings at maintenance are substantial — roughly $235/month, $14,100 over five years.

What you should know about the lane

This is personal-import. Mechanics of the lane:

• Lead time: 2 weeks standard, 2-4 weeks with customs variance. Tracking active 24-48h after dispatch.
• Cold chain: Pens require 2-8°C handling end-to-end. Suppliers ship insulated; LiberaCure doesn't warehouse or break the chain.
• Jurisdiction: US allowance is the FDA personal-importation policy (90-day supply, prescription drug for personal use, non-controlled). Australia uses the TGA Personal Importation Scheme — also up to a 3-month supply, prescription required for Schedule 4 drugs, semaglutide qualifies. UK and Canada have analogous personal-import lanes. None of these are smuggling; they're policy.
• Stock fluctuation: Pen-format inventory moves in waves more than tablet generics. Dose strength availability shifts week to week. If a specific dose is non-negotiable, ask before you order.
• Payment: Crypto only (BTC, USDT TRC-20, LTC, XMR, ETH via NOWPayments). That's the operational choice that lets the markup tier sit where it does — card-network and personal-import processor premiums get skipped.
• If a package is lost: Reship once free. Second reship also free. Crypto refund (BTC/ETH/USDT) on the third failure. Email reply 24-48h ([email protected]), no live chat, no phone.

This isn't the deepest customer-service operation in the lane — that's where the larger personal-import sites outspend us — but the policy is one screen, not buried in a PDF.

The harder truth nobody mentions

The brand vs generic question is interesting but it's the second-most-important question in this whole space.

The first one is: are you prepared to take this drug for ten years.

Semaglutide does not retrain a system. The STEP-1 trial extension (Wilding 2022, Diabetes Obes Metab) followed 327 responders for one year off-drug. Mean weight regain: ~67% of the loss. Not because participants stopped trying. Because the drug was doing the work, and removing the drug removes the effect.

If you're going to start, plan the maintenance dose pricing on day one. That's where the $80,000+ five-year cost difference between brand and generic actually shows up — in year four when you realize you're still on it and your pharmacy won't refill the prior auth this time.

For the deeper read on the regain mechanism: see Most Ozempic users gain 67% of the weight back within a year of stopping. For the full GLP-1 framework: GLP-1 comprehensive guide. For the single-brand cost focus on Wegovy vs Noveltreat alone: Wegovy retails at $1,800/mo. Noveltreat launched at $80. For the titration ladder mechanics: Wegovy titration ladder 0.25 to 2.4mg. For NovoCare vs telehealth pricing: NovoCare vs telehealth GLP-1 pricing.

A note on bias.

We route semaglutide orders. Be aware of that.

LiberaCure routes orders to licensed personal-import pharmacies. Noveltreat (by Sun Pharma), Semasize / Semasize Plus (by Alkem), Sematrinity (by Sun Pharma), and Obeda (by Dr. Reddy's) are all in our catalog — those are the four brands this article walks through. So we have a financial reason to want this article to lead you toward "give it a try."

Read this with that in mind. The teardown above is what I'd tell a friend asking which generic to start with, not what maximizes reorder rate. If Hims's Wegovy Pen at $199 or NovoCare Direct at $349 is the right fit for you, take that lane. The peptide is the same in all of them.

Sources:

• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021;384:989-1002. PMID 33567185
• Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP-1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564. PMID 35441470
• Rubino DM et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP-4). JAMA 2021;325(14):1414-1425.
• Novo Nordisk Wegovy / Ozempic SmPC and US prescribing information, current revision; NovoCare Direct self-pay program ($349-499/mo).
• Hims & Hers Wegovy Pen pricing announcement, 2026; volume contract with Novo Nordisk.
• CDSCO / DCGI public approval listings for semaglutide injection generics: Noveltreat (Sun Pharma), Semasize / Semasize Plus (Alkem), Sematrinity (Sun Pharma), Obeda (Dr. Reddy's), launched March-April 2026.
• IBEF (India Brand Equity Foundation), Indian Pharmaceutical Industry Report, 2024 — Sun Pharma, Dr. Reddy's, Alkem revenue and ANDA filing data.
• FDA Drug Shortages Database — semaglutide shortage resolved February 21, 2025 (503A grace through April 22, 2025).

— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.